Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC

NCT07754123 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic NSCLC

Interventions

DRUG: HS-10504
DRUG: platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin)

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.